AllStripes Raises $50M in Series B Financing

Nancy Yu, AllStripes CEO and Co-founder - Photo by Alison Yin/Alison Yin Photography
Nancy Yu, AllStripes CEO and Co-founder

AllStripes, a San Francisco, CA-based healthcare technology company dedicated to advancing treatments for people affected by rare diseases, raised $50m in Series B financing.

The round was led by Lux Capital, joined by JAZZ Venture Partners, Spark Capital, Medidata Solutions (a Dassault Systèmes company), McKesson Ventures, and Maveron, along with angel investors including Arif Nathoo, CEO of Komodo Health, and Leila Zegna, Director of the Kabuki Syndrome Foundation.

The company intends to use the funds to:

  • launch 100 new rare disease research programs
  • expand global operational presence, technology and data automation enhancements to improve research insights,
  • develop the platform capabilities to enhance the user experience and strengthen the life sciences offerings, and
  • continue to invest in growing the team to support creating the playbook for rare disease research.

Founded by CEO Nancy Yu and technology developer Onno Faber, following his diagnosis and journey with the rare disease neurofibromatosis type 1, AllStripes is a healthcare technology company dedicated to advancing new treatments for people with rare diseases. The company has developed a technology platform that generates regulatory-ready evidence to accelerate rare disease research and drug development, as well as a patient application that empowers patients and families to securely participate in treatment research online and benefit from their own medical data.

AllStripes is currently partnering with more than 30 patient advocacy organizations across its 40 conditions, supporting more than 3,000 users to date. It collaborates with various biopharmaceutical companies and other entities on real-world evidence studies, including: HemoShear Therapeutics, Inc., Orphan Disease Center at the University of Pennsylvania, Taysha Gene Therapies, Inc., UCB Biopharma SRL, and Novartis Pharma AG. These joint research programs aim to enhance clinical understanding of rare disease treatment research. AllStripes and the University of Pennsylvania’s Orphan Disease Center are focused on clinical understanding of Lesch-Nyhan disease and Crigler Najjar syndrome type 1, with the goal of facilitating therapeutic discovery for both conditions. One of AllStripes’ most recent partnerships with HemoShear Therapeutics aims to gather real-world evidence on patients’ medical experience with serious metabolic diseases through the Journey to Understand MMA and PA (JUMP) study.